Skip to main content
Equibles
KPTI logo

KPTI · Karyopharm Therapeutics Inc. · Metrics

Track KPTI — free

Use KPTI with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research KPTI.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.48 -0.04 (-6.84%) At close · Oct 26
Russell 2000 member Rebalance outlook locked
Going-concern doubt — flagged Aug 13, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Based on our current business plan and current capital resources, combined with the uncertainty regarding the availability of additional funding or other strategic alternatives and considering our debt service obligations and financial covenant to maintain minimum liquidity, we have concluded that there is substantial doubt regarding our ability to continue as a going concern within one year after the date the accompanying condensed consolidated financial statements are issued.”
View the 10-Q filed Aug 13, 2026
Market Cap
$11.74M
Shares
22.68M
Volume · Oct 26 1.37M Avg daily vol (3M) 1.94M

KPTI metrics

70 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.48
Market cap
$11.74M

Price action

20 metrics
Price change (1W)
+32.7%
Price change (30D)
-68.1%
Price change (3M)
-93.0%
Price change (6M)
-94.0%
Price change (YTD)
-93.0%
Price change (1Y)
-91.6%
Trailing year
Price change (5Y)
—
52-week high
$10.67
52-week low
$0.32
Change from 52-week high
-95.1%
Change from 52-week low
+64.3%
Annualized volatility
128.3%
Annualized volatility (3M)
204.3%
Beta
0.7
RSI (14D)
30.9
Price vs SMA 50
-61.6%
Price vs SMA 200
-91.7%
Avg volume (3M)
1.93M
Relative volume
1.0
Average dollar volume
$3.47M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
22.68M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
0.1×
reciprocal yield 1,249.2%
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-1,914.7%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
2.2×
reciprocal yield 45.7%
EV / revenue historical average (5Y)
2.2×
reciprocal yield 45.7%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-13

Profitability

9 metrics
Gross margin
—
Operating margin
-56.2%
Trailing 12 months
Net margin
-153.3%
Gross profit (TTM)
—
Operating profit (TTM)
−$82.35M
Net income (TTM)
−$224.74M
Trailing 12 months
Diluted EPS (TTM)
$-14.40
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$-16.00

Growth

11 metrics
Revenue growth YoY
-11.9%
Year over year
Net income growth YoY
—
Revenue (TTM)
$146.62M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+235.7%
Year over year · more shares
Revenue CAGR (3Y)
-2.4%
Revenue CAGR (5Y)
+6.2%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
-201.9%
Debt / equity
—
Current ratio
0.8
EBITDA (TTM)
−$177.09M
Free cash flow (TTM)
—
Quick ratio
0.8
Interest coverage
-1.7
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$54.98M
Total assets
$111.32M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$65.35M
Capital expenditures (TTM)
$0
R&D (TTM)
$120.97M
SG&A (TTM)
$101.98M
Stock compensation (TTM)
$11.64M
R&D / revenue
82.5%
Stock compensation / revenue
7.9%

Ownership (13F)

9 metrics
13F filers
100
13F filer change QoQ
+16
Institutional ownership
100.7%
Conviction holders (share of 13F filers)
2.1%
Crowding (high-turnover and private-fund holders)
50.8%
Private-fund adviser ownership
47.5%
Active holders' share change QoQ
+3.9%
Holder tenure
7.0
Price vs estimated holder cost
-5.2%

Ownership (registered funds)

1 metrics
Index-fund ownership
9.2%

Short interest

3 metrics
Short interest
32.0%
Latest settlement · 4.8 days to cover
Days to cover
4.8d
Short-squeeze score
72 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$2,135
Insider-sentiment score
49 / 100

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1503802 CUSIP 48576U205 13F (30d) 10 filings 10 filers Visit website Investor relations